Cardiothoracic Imaging| Volume 94, P50-55, February 2023

Access to cardiac PET/CT by sarcoidosis patients and cost-effectiveness analysis of cardiac PET/MR compared to the standard of care

Published:December 01, 2022DOI:


      • Patients with access to cardiac PET/CT are not representative of the patient population most likely to have CS in this limited study evaluation.
      • Cardiac PET/MR has long-term cost-effectiveness compared to the standard of care imaging of cardiac MR followed by cardiac PET/CT sequentially.
      • Same day cardiac PET/MR had overall improved quality of life-years for CS patients compared to the standard of care.



      Cardiac sarcoidosis is associated with a high mortality rate. Given multiple barriers to obtaining cardiac PET imaging, we suspect individuals with access to this imaging modality are not representative of the Sarcoid patient population, which in the United States are predominantly Black females.


      To evaluate the demographics of patients with cardiac PET access and the cost-effectiveness of cardiac PET/MR imaging relative to standard of care.


      This is a retrospective, observational study. The demographic information of patients with suspected cardiac sarcoidosis and cardiac PET/CT imaging within a national registry of sarcoidosis were reviewed (n = 4561). An individual-level, continuous, time-state transition model was used for the evaluation of long-term cost-effectiveness for the combined cardiac PET/MR compared to standard of care cardiac MR followed by cardiac PET/CT.


      Patients who underwent cardiac PET in the national registry had 88.35% higher odds of being male (p < 0.001) and 43.82% higher odds of being White (p = 0.003) than their counterparts who did not have cardiac PET imaging. Combined cardiac PET/MR had overall lower total lifetime costs ($8761 vs $10,777) and overall improved expected quality of life-years compared to the standard of care (0.77 vs 0.69).

      Conclusion and relevance

      The findings suggest that patients with access to cardiac PET/CT are not representative of the patient population most likely to have cardiac sarcoidosis in this limited study evaluation. Universal insurance coverage should be considered for Cardiac PET imaging as same day cardiac PET and MR imaging has potential long-term cost and quality of life benefit.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dweck M.R.
        • Abgral R.
        • Trivieri M.G.
        • Robson P.M.
        • Karakatsanis N.
        • Mani V.
        • et al.
        Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis.
        JACC Cardiovasc Imaging. 2018; 11: 94-107
        • Swigris J.J.
        • Olson A.L.
        • Huie T.J.
        • Fernandez-Perez E.R.
        • Solomon J.
        • Sprunger D.
        • et al.
        Sarcoidosis-related mortality in the United States from 1988 to 2007.
        Am J Respir Crit Care Med. 2011; 183: 1524-1530
        • Iwai K.
        • Tachibana T.
        • Takemura T.
        • Matsui Y.
        • Kitaichi M.
        • Kawabata Y.
        Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan.
        Acta Pathol Jpn. 1993; 43: 372-376
        • Morimoto T.
        • Azuma A.
        • Abe S.
        • Usuki J.
        • Kudoh S.
        • Sugisaki K.
        • et al.
        Epidemiology of sarcoidosis in Japan.
        Eur Respir J. 2008; 31: 372-379
        • Baughman R.P.
        • Teirstein A.S.
        • Judson M.A.
        • Rossman M.D.
        • Yeager H.
        • Bresnitz E.A.
        • et al.
        Clinical characteristics of patients in a case control study of sarcoidosis.
        Am J Respir Crit Care Med. 2001; 164: 1885-1889
      1. Design of a case control etiologic study of sarcoidosis (ACCESS).
        J Clin Epidemiol. 1999; 52: 1173-1186
      2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.
        Am J Respir Crit Care Med. 1999; 160: 736-755
        • Rybicki B.A.
        • Major M.
        • Popovich J.
        • Maliarik M.J.
        • Iannuzzi M.C.
        Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.
        Am J Epidemiol. 1997; 145: 234-241
        • Yoshinaga K.
        • Miyagawa M.
        • Kiso K.
        • Ishida Y.
        Japanese guidelines for cardiac sarcoidosis.
        Ann Nucl Cardiol. 2017; 3: 121-124
      3. Cardiac MRI vs. PET for the evaluation of cardiac sarcoidosis: consider MRI first. Am Coll Cardiol n.d. (accessed December 8, 2020).

        • Ferreira V.M.
        • Schulz-Menger J.
        • Holmvang G.
        • Kramer C.M.
        • Carbone I.
        • Sechtem U.
        • et al.
        Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.
        J Am Coll Cardiol. 2018; 72: 3158-3176
        • Aitken M.
        • Chan M.V.
        • Urzua Fresno C.
        • Farrell A.
        • Islam N.
        • McInnes M.D.F.
        • et al.
        Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and meta-analysis.
        Radiology. 2022; 304: 566-579
        • Wicks E.C.
        • Menezes L.J.
        • Barnes A.
        • Mohiddin S.A.
        • Sekhri N.
        • Porter J.C.
        • et al.
        Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis.
        Eur Heart J - Cardiovasc Imaging. 2018; 19: 757-767
        • Incerti D.
        • Jansen J.P.
        hesim: Health Economic Simulation Modeling and Decision Analysis.
        ArXiv210209437 Stat, 2021
        • Arkema E.V.
        • Cozier Y.C.
        Epidemiology of sarcoidosis: current findings and future directions.
        Ther Adv Chronic Dis. 2018; 9: 227-240
        • Vita T.
        • Okada D.R.
        • Veillet-Chowdhury M.
        • Bravo P.E.
        • Mullins E.
        • Hulten E.
        • et al.
        Complementary value of cardiac magnetic resonance imaging and positron emission Tomography/Computed tomography in the assessment of cardiac sarcoidosis.
        Circ Cardiovasc Imaging. 2018; 11e007030
        • Cox C.E.
        • Donohue J.F.
        • Brown C.D.
        • Kataria Y.P.
        • Judson M.A.
        Health-related quality of life of persons with sarcoidosis.
        Chest. 2004; 125: 997-1004
        • Rice J.B.
        • White A.
        • Lopez A.
        • Nelson W.W.
        High-cost sarcoidosis patients in the United States: patient characteristics and patterns of health care resource utilization.
        J Manag Care Spec Pharm. 2017; 23: 1261-1269
        • Brouwer W.B.F.
        • Niessen L.W.
        • Postma M.J.
        • Rutten F.F.H.
        Need for differential discounting of costs and health effects in cost effectiveness analyses.
        BMJ. 2005; 331: 446-448
        • Grutters J.C.
        • van den Bosch J.M.M.
        Corticosteroid treatment in sarcoidosis.
        Eur Respir J. 2006; 28: 627-636
      4. Sarcoidosis - American Family Physician n.d. (accessed June 21, 2021).

        • Nardi A.
        • Brillet P.-Y.
        • Letoumelin P.
        • Girard F.
        • Brauner M.
        • Uzunhan Y.
        • et al.
        Stage IV sarcoidosis: comparison of survival with the general population and causes of death.
        Eur Respir J. 2011; 38: 1368-1373
        • Lynch J.P.
        • Hwang J.
        • Bradfield J.
        • Fishbein M.
        • Shivkumar K.
        • Tung R.
        Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment.
        Semin Respir Crit Care Med. 2014; 35: 372-390
        • Sgard B.
        • Brillet P.-Y.
        • Bouvry D.
        • Djelbani S.
        • Nunes H.
        • Meune C.
        • et al.
        Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.
        Clin Radiol. 2019; 74: 81.e9-81.e18
        • Cooper L.T.
        • Baughman K.L.
        • Feldman A.M.
        • Frustaci A.
        • Jessup M.
        • Kuhl U.
        • et al.
        The role of endomyocardial biopsy in the management of cardiovascular disease.
        Circulation. 2007; 116: 2216-2233
        • Uemura A.
        • Morimoto S.
        • Hiramitsu S.
        • Kato Y.
        • Ito T.
        • Hishida H.
        Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies.
        Am Heart J. 1999; 138: 299-302
        • Hena K.M.
        Sarcoidosis epidemiology: race matters.
        Front Immunol. 2020; 11537382
        • Cozier Y.C.
        • Berman J.S.
        • Palmer J.R.
        • Boggs D.A.
        • Serlin D.M.
        • Rosenberg L.
        Sarcoidosis in Black women in the United States: data from the Black women’s health study.
        Chest. 2011; 139: 144-150
        • Coquart N.
        • Cadelis G.
        • Tressières B.
        • Cordel N.
        Epidemiology of sarcoidosis in Afro-Caribbean people: a 7-year retrospective study in Guadeloupe.
        Int J Dermatol. 2015; 54: 188-192
      5. Bureau UC. Income and Poverty in the United States: 2020. CensusGov n.d. (accessed April 17, 2022).

      6. Decision Memo for Positron Emission Tomography (FDG) (CAG-00065N) n.d. (accessed December 8, 2020).

        • Owens D.K.
        Interpretation of cost-effectiveness analyses.
        J Gen Intern Med. 1998; 13: 716-717